人源化抗CD19与抗BCMA CAR-T联合治疗复发难治多发性骨髓瘤的单臂2期试验
该单中心单臂2期试验纳入22例复发难治多发性骨髓瘤患者,21例接受人源化抗CD19与鼠源抗BCMA CAR-T联合输注,中位随访179天时20例(95%)达总体缓解,9例(43%)达严格完全缓解,最常见不良事件为细胞因子释放综合征(19/21,90%),1例死于脑出血。
要点
- 联合输注在复发难治骨髓瘤中可行,总体缓解率95%,严格完全缓解率43%。
- 细胞因子释放综合征发生率90%,多为1-2级(86%)。
- 血液学毒性常见,3级及以上中性粒细胞减少86%、贫血62%、血小板减少62%。
核心结论
- 人源化抗CD19与抗BCMA CAR-T联合输注在复发难治多发性骨髓瘤中可行,初步活性值得随机试验进一步验证。
研究设计与样本
- 单中心、单臂2期试验,在中国徐州医科大学附属医院开展,纳入22例18-69岁复发难治多发性骨髓瘤患者,21例接受CAR-T输注并可评估安全性和活性。
主要发现
- 中位随访179天(IQR 72-295),21例中20例(95%)达总体缓解。
- 缓解包括9例(43%)严格完全缓解、3例(14%)完全缓解、5例(24%)非常好的部分缓解、3例(14%)部分缓解。
- 细胞因子释放综合征19例(90%),其中18例(86%)为1-2级。
- 严重不良事件最常见为血液学毒性,20例(95%)发生。
- 3级及以上不良事件包括中性粒细胞减少18例(86%)、贫血13例(62%)、血小板减少13例(62%)。
关键数值与推荐
- 淋巴细胞清除方案:氟达拉滨30mg/m2每日×3天,环磷酰胺750mg/m2每日×1天。
- CAR-T输注剂量:人源化抗CD19 CAR-T 1×10^6细胞/kg,鼠源抗BCMA CAR-T 1×10^6细胞/kg。
- 主要终点为总体缓解比例,依据国际骨髓瘤工作组标准评估。
- 1例患者死于脑出血,认为与持续血小板减少相关;无死亡判定为治疗相关。
临床怎么用
- 联合CAR-T方案可作为复发难治多发性骨髓瘤的潜在治疗选择,需关注细胞因子释放综合征和血液学毒性管理。
局限性
- 单中心、单臂设计,样本量小(21例可评估),随访时间较短,结论需随机试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has been shown to have activity in patients with relapsed or refractory multiple myeloma. Reports have suggested that a small subgroup of less differentiated myeloma clones express CD19 and anti-CD19 CAR T-cell therapy has shown activity in some of these patients. We aimed to assess the activity and safety of a combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma. METHODS: We did a single-centre, single-arm, phase 2 trial at the Affiliated Hospital of Xuzhou Medical University in China. Patients were eligible if they were aged 18-69 years, had histologically confirmed multiple myeloma, a Karnofsky Performance Score of 50 points or more, and met the International Myeloma Working Group diagnostic criteria for relapsed or refractory disease. Fludarabine (three daily doses of 30mg/m2) and cyclophosphamide (one daily dose of 750 mg/m2) were used to deplete lymphocytes before infusion of humanised anti-CD19 CAR T cells (1 × 106 cells per kg) and murine anti-BCMA CAR T cells (1 × 106 cells per kg). The primary outcome was the proportion of patients who achieved an overall response. Responses were assessed according to the International Myeloma Working Group criteria. This study is registered with the Chinese Clinical Trial Registration Center, number ChiCTR-OIC-17011272. FINDINGS: From May 1, 2017, to Jan 20, 2019, 22 patients were enrolled and 21 received an infusion of CAR T cells and were evaluable for safety and activity analyses. At a median follow-up of 179 days (IQR 72-295), 20 (95%) of 21 patients had an overall response, including nine (43%) stringent complete responses, three (14%) complete responses, five (24%) very good partial responses, and three (14%) partial responses. The most common adverse events included cytokine release syndrome (19 [90%] of 21), including 18 patients (86%) with grade 1-2 cytokine release syndrome. The most common serious adverse events were haematological toxicities, which occurred in 20 (95%) of 21 patients. Common grade 3 or higher adverse events included neutropenia (18 [86%]), anaemia (13 [62%]), and thrombocytopenia (13 [62%]). One patient died due to cerebral hemorrhage, which was considered related to sustained thrombocytopenia. No deaths were judged to be treatment-related. INTERPRETATION: Our results confirm that combined infusion of humanised anti-CD19 and anti-BCMA CAR T cells is feasible in patients with relapsed or refractory multiple myeloma, and the preliminary activity observed warrants further investigation in randomised trials. This dual CAR-T cell combinations might be a promising treatment option for relapsed or refractory multiple myeloma. FUNDING: National Natural Science Foundation of China, Natural Science Foundation, Key Research and Development Plan of Jiangsu.
引用
- Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019. PMID: 31378662. doi:10.1016/S2352-3026(19)30115-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。